Ionis to repurchase $30.2 million of 0.125% convertible notes

By Wendy Van Sickle

Columbus, Ohio, Aug. 23 – Ionis Pharmaceuticals Inc. entered on Aug. 21 and Aug. 23 into separate privately negotiated agreements with some holders of its 0.125% convertible senior notes due 2024 to repurchase $30.2 million principal amount of the convertibles for $29.2 million, according to an 8-K filing with the Securities and Exchange Commission.

The company may seek to retire or repurchase additional convertibles from time to time in open market purchases, privately negotiated transactions or otherwise, depending on market conditions.

There were $548.9 million of the convertible notes originally issued.

Ionis Pharmaceuticals is a Carlsbad, Calif.-based biotech company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.